IBDEI0I9 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8215,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8215,1,3,0)
 ;;=3^Obesity,Unspec
 ;;^UTILITY(U,$J,358.3,8215,1,4,0)
 ;;=4^E66.9
 ;;^UTILITY(U,$J,358.3,8215,2)
 ;;=^5002832
 ;;^UTILITY(U,$J,358.3,8216,0)
 ;;=E74.39^^39^394^16
 ;;^UTILITY(U,$J,358.3,8216,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8216,1,3,0)
 ;;=3^Intestinal Carbohydrate Absorption Disorder NEC
 ;;^UTILITY(U,$J,358.3,8216,1,4,0)
 ;;=4^E74.39
 ;;^UTILITY(U,$J,358.3,8216,2)
 ;;=^5002928
 ;;^UTILITY(U,$J,358.3,8217,0)
 ;;=E83.30^^39^394^28
 ;;^UTILITY(U,$J,358.3,8217,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8217,1,3,0)
 ;;=3^Phosphorus Metabolism Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,8217,1,4,0)
 ;;=4^E83.30
 ;;^UTILITY(U,$J,358.3,8217,2)
 ;;=^5002997
 ;;^UTILITY(U,$J,358.3,8218,0)
 ;;=E83.51^^39^394^9
 ;;^UTILITY(U,$J,358.3,8218,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8218,1,3,0)
 ;;=3^Hypocalcemia
 ;;^UTILITY(U,$J,358.3,8218,1,4,0)
 ;;=4^E83.51
 ;;^UTILITY(U,$J,358.3,8218,2)
 ;;=^60542
 ;;^UTILITY(U,$J,358.3,8219,0)
 ;;=E83.52^^39^394^7
 ;;^UTILITY(U,$J,358.3,8219,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8219,1,3,0)
 ;;=3^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,8219,1,4,0)
 ;;=4^E83.52
 ;;^UTILITY(U,$J,358.3,8219,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,8220,0)
 ;;=E87.5^^39^394^8
 ;;^UTILITY(U,$J,358.3,8220,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8220,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,8220,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,8220,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,8221,0)
 ;;=E89.2^^39^394^30
 ;;^UTILITY(U,$J,358.3,8221,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8221,1,3,0)
 ;;=3^PostProcedural Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,8221,1,4,0)
 ;;=4^E89.2
 ;;^UTILITY(U,$J,358.3,8221,2)
 ;;=^5003037
 ;;^UTILITY(U,$J,358.3,8222,0)
 ;;=E89.6^^39^394^29
 ;;^UTILITY(U,$J,358.3,8222,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8222,1,3,0)
 ;;=3^PostProcedural Adrenocortical Hypofunction
 ;;^UTILITY(U,$J,358.3,8222,1,4,0)
 ;;=4^E89.6
 ;;^UTILITY(U,$J,358.3,8222,2)
 ;;=^5003042
 ;;^UTILITY(U,$J,358.3,8223,0)
 ;;=L68.0^^39^394^6
 ;;^UTILITY(U,$J,358.3,8223,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8223,1,3,0)
 ;;=3^Hirsutism
 ;;^UTILITY(U,$J,358.3,8223,1,4,0)
 ;;=4^L68.0
 ;;^UTILITY(U,$J,358.3,8223,2)
 ;;=^5009262
 ;;^UTILITY(U,$J,358.3,8224,0)
 ;;=M80.00XA^^39^394^2
 ;;^UTILITY(U,$J,358.3,8224,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8224,1,3,0)
 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
 ;;^UTILITY(U,$J,358.3,8224,1,4,0)
 ;;=4^M80.00XA
 ;;^UTILITY(U,$J,358.3,8224,2)
 ;;=^5013363
 ;;^UTILITY(U,$J,358.3,8225,0)
 ;;=M81.0^^39^394^3
 ;;^UTILITY(U,$J,358.3,8225,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8225,1,3,0)
 ;;=3^Age-Related Osteoporosis w/o Fx
 ;;^UTILITY(U,$J,358.3,8225,1,4,0)
 ;;=4^M81.0
 ;;^UTILITY(U,$J,358.3,8225,2)
 ;;=^5013555
 ;;^UTILITY(U,$J,358.3,8226,0)
 ;;=M85.80^^39^394^26
 ;;^UTILITY(U,$J,358.3,8226,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8226,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,8226,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,8226,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,8227,0)
 ;;=N62.^^39^394^5
 ;;^UTILITY(U,$J,358.3,8227,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8227,1,3,0)
 ;;=3^Gynecomastia
 ;;^UTILITY(U,$J,358.3,8227,1,4,0)
 ;;=4^N62.
 ;;^UTILITY(U,$J,358.3,8227,2)
 ;;=^5015790
 ;;^UTILITY(U,$J,358.3,8228,0)
 ;;=E66.3^^39^394^27
